CPHI chinapharmaholdings.com: Forward P/S Multiple

China Pharma Holdings Inc. - graphic logo of issuer CPHI

China Pharma Holdings (CPHI) maintains a high reputation for developing affordable neuropsychiatric medications. Changes in the forward P/S ratio help identify a reversal in the asset's fundamental value in a timely manner, where 5.20 serves as the base parameter value. The company is expanding its digital services by recruiting IT specialists to manage pharmacy chains. Supplying generic drugs to state hospitals makes the business a critical link in China's healthcare system.

China Pharma Holdings, Inc. - CPHI Forward Price to Sales (period 07/04/2022 - 11/18/2026)

China Pharma Holdings, Inc. - analytical breakdowns and key metrics (CPHI)

Fundamental company analysis:China Pharma Holdings, Inc. (CPHI)
Original product of chinapharmaholdings.com

Forward P/S determines the market value of an asset relative to expected revenue, allowing for an assessment of the premium paid for future growth rates. By analyzing the modeled P/S of China Pharma Holdings (CPHI), an investor can identify unjustified market optimism amid compressing generic margins in China and pressure from government procurement, which limit the business scaling potential of China Pharma Holdings.